Market revenue in 2023 | USD 346.4 million |
Market revenue in 2030 | USD 850.1 million |
Growth rate | 13.7% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer's disease |
Fastest growing segment | Alzheimer's Disease |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 35.91% in 2023. Horizon Databook has segmented the Japan immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
The discovery, development, and commercialization of novel biomarkers for the diagnosis of neurodegenerative diseases, such as Alzheimer’s, positively contribute to market growth. For instance, in December 2022, Sysmex Corporation received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) for its blood test assay kit to measure the level of amyloid beta in the blood in Japan.
This assay kit uses a small amount of blood for measuring the amyloid beta levels using an automated immunoassay system HISCL 800 & HISCL 5,000 and provides results in 17 minutes. It avoids unnecessary utilization of blood for testing purposes, subsequently increasing demand for such products in the future.
Organizations such as Japan Biological Informatics Consortium (JBIC), which are engaged in biomarkers development, enable collaborations and provision of services for biomarker research, thereby contributing to the larger revenue share of the Asia Pacific biomarkers market.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan immunoassay for neurological biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Japan immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account